USE OF STRUCTURALLY ENHANCED FATTY ACIDS CONTAINING SULPHUR FOR PREVENTING AND OR TREATING NON ALCOHOLIC STEATOHEPATITIS
The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R 1 , R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R 3 , and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R 2 , R 3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
1 . A compound of Formula (I)
wherein
R 2 and R 3 are independently chosen from the group of a hydrogen atom and linear, branched and/or cyclic C 1 -C 6 alkyl groups, with the proviso that R 2 and R 3 are not both hydrogen;
X is a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylic ester, a glyceride or a phospholipid;
or a pharmaceutically acceptable salt, solvate, or solvate of such salt thereof,
for preventing and/or treating non-alcoholic steatohepatitis.
2 . The compound according to claim 1 for use according to claim 1 , wherein R 2 and R 3 are independently chosen from a hydrogen atom, a methyl group, an ethyl group, a n-propyl group and an isopropyl group.
3 . The compound according to claim 1 , wherein R 2 and R 3 are independently chosen from C 1 -C 6 alkyl groups.
4 . The compound according to claim 1 , wherein R 2 and R 3 are ethyl groups.
5 . The compound according to claim 1 , wherein X is a carboxylic acid.
6 . The compound according to claim 1 , wherein X is a C 1 -C 6 alkyl ester.
7 . The compound according to claim 1 , wherein X is chosen from the group of a methyl ester, an ethyl ester, an isopropyl ester, a n-butyl ester and a tert-butyl ester.
8 . The compound according to claim 1 , wherein X is selected from a methyl ester and an ethyl ester.
9 . The compound according to claim 1 , wherein X is a glyceride chosen from a triglyceride, a 1,2-diglyceride, a 1,3-diglyceride, a 1-monoglyceride and 2-monoglyceride.
10 . The compound according to claim 1 , wherein the compound is present in the form of an enantiomer, a diastereomer or a mixture thereof.
11 . The compound according to claim 1 , wherein the compound is present in its R form, in its S form or in racemic form.
12 . The compound according to claim 1 , wherein R 2 and R 3 are ethyl groups and X is a carboxylic acid.
13 . The compound according to claim 1 , wherein said compound is administered in a dose of between about 5 mg to about 2 g per dose.
14 . The compound according to claim 1 , wherein said compound is administered in a dose of between about 200 mg to about 800 mg per dose.
15 . The compound according to claim 1 , wherein said compound is administered once daily.
16 . The compound according to claim 1 , wherein said compound is formulated as a pharmaceutical composition for oral administration.
17 . The compound according to claim 1 , wherein the pharmaceutical composition is in the form of a gelatin capsule or a tablet.
18 . The compound according to claim 1 , wherein the pharmaceutical composition further comprises at least one binder, excipient, diluent, or any combinations thereof.
19 . The compound according to claim 16 , wherein the pharmaceutical composition further comprises an antioxidant.
20 . The compound according to claim 19 , wherein the antioxidant is chosen from tocopherol, BHA, and BHT, or mixtures thereof.
21 . 2-ethyl-2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenylthio)butanoic acid
or a pharmaceutically acceptable salt or ester thereof, for preventing and/or treating non-alcoholic steatohepatitis.
22 . The compound according to claim 21 , wherein this is administered in a dose of between about 200 mg to about 800 mg per dose.
23 . A method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I):
wherein R 2 and R 3 are independently chosen from the group of a hydrogen atom and linear, branched and/or cyclic C 1 -C 6 alkyl groups, with the proviso that R 2 and R 3 are not both hydrogen; X is a carboxylic acid or a derivative thereof, wherein the derivative is a carboxylic ester, a glyceride, or a phospholipid; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
24 . The method according to claim 23 , wherein R 2 and R 3 are ethyl groups and X is a carboxylic acid.